CTRI/2023/01/049098尚未招募未知
Evaluation of irritation potential of Skin Care formulation on healthy human subjects
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Asian Indian male and female subjects.
- •2. Healthy human subjects (no infectious and evolutive pathology which could make the subject
- •vulnerable and stop the study, no pathology which could interfere with the study, no symptom in
- •the process of an exploratory check up)
- •3. Between 18 and 65 years of age.
- •4. Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar)
排除标准
- •1 For female: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
- •2 Having refused to give his/her assent by not signing the consent form
- •3 Taking part in another study liable to interfere with this study
- •4 Being diabetic.
- •5 Being asthmatic.
- •6 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol).
- •7 Having cutaneous hypersensitivity (except in the case of studies with evaluation of sensitive skin).
- •8 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
- •9 Having undergone a surgery requiring a general anaesthesia of more than one hour in the past 6 months.
- •10 Having changed his/her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit.
- •11 The day of the patch application: no cosmetic product must be used (test site clean with water only). Refusing to follow the restrictions below during the study: - For female: Do not become pregnant nor breastfeed. - Do not take part in another study liable to interfere with this study - Do not take medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, and antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol). - Do not change his/her cosmetic habits apart from the particular conditions mentioned in the protocol, on the studied anatomic unit
- •12 Having eczema, psoriasis, lichen plan, vitiligo whatever the considered area
- •13 Having disorder of the healing (whatever the considered area) • Having a rhinitis, allergic conjunctivitis, or rhino sinusitis
- •14 Having an allergy to perfumes and/or conservatives in cosmetic products
- •15 Having an allergy to plaster
- •16 Having a food allergy
- •17 Having a cardiovascular pathology (taking a beta blocker treatment)
- •18 Having immunosuppressive drugs, such as cyclophosphamide, methotrexate, azathioprine, etc.
- •19 Taking a retinoid-based treatment by general or oral route
- •20 Taking specific treatment on the back.
- •21 Having taken an anti-histaminic treatment in the last 2 weeks preceding the start of the study
- •22 Having miliaria (prickly heat) on the back.
- •23 Presenting too many naevus on the back
- •24 Having high pilosity on the back.
- •25 Refusing to follow the restrictions below during the study: - During the first 24 hours (after patch application), neither cosmetic products nor water must be applied on the back. - Till the follow up period of until T8 days, only water is accepted from the first reading i.e., T2 days (24 hours after the patch removal). - Do not practice an intensive sport activity during the first 24 hours (until the removal of the patches) - Do not expose the back to the sun.
研究者
相似试验
尚未招募
不适用
Safety assessment of productCTRI/2021/07/034994Mosaic wellness pvt ltd
尚未招募
不适用
Safety assessment of skin care formulationsCTRI/2021/07/035173Kama Ayurveda Pvt Ltd
尚未招募
不适用
Safety assessment of skincare formulationsCTRI/2022/01/039173Kama Ayurveda Pvt Ltd
尚未招募
不适用
Safety assessment of skin care formulatioCTRI/2021/06/034186Kama Ayurveda Pvt Ltd
已完成
不适用
Safety assessment of skincare formulations.CTRI/2021/07/034995TTK HEALTHCARE LIMITED24